Transdermal Delivery of Chemotherapeutics: Strategies, Requirements, and Opportunities
Abstract
Chemotherapeutic drugs are primarily administered to cancer patients via oral or parenteral routes. The use of transdermal drug delivery could potentially be a better alternative to decrease the dose frequency and severity of adverse or toxic effects associated with oral or parenteral administration of chemotherapeutic drugs. The transdermal delivery of drugs has shown to be advantageous for the treatment of highly localized tumors in certain types of breast and skin cancers. In addition, the transdermal route can be used to deliver low-dose chemotherapeutics in a sustained manner. The transdermal route can also be utilized for vaccine design in cancer management, for example, vaccines against cervical cancer. However, the design of transdermal formulations may be challenging in terms of the conjugation chemistry of the molecules and the sustained and reproducible delivery of therapeutically efficacious doses. In this review, we discuss the nano-carrier systems, such as nanoparticles, liposomes, etc., used in recent literature to deliver chemotherapeutic agents. The advantages of transdermal route over oral and parenteral routes for popular chemotherapeutic drugs are summarized. Furthermore, we also discuss a possible in silico approach, Formulating for Efficacy™, to design transdermal formulations that would probably be economical, robust, and more efficacious.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jun 26, 2021
- Source ID
- 10.3390/pharmaceutics13070960
Entities
People
- Amit K. Tiwari
- David Terrero
- Mariam S Abou-Dahech
- R. Jayachandra Babu
- Rabin Neupane
- Rinda Devi Bachu
- Sai H S Boddu
Organizations
- Susan G. Komen for the Cure
- United States Department of Defense